Dr. Kronenberg served as PI in several studies on genetic risk factors for atherosclerosis and biomarkers for the progression of CKD including the Mild to Moderate Kidney Disease Study00 (MMKD). He served as a workgroup member of the NKF K/DOQI Guidelines on Cardiovascular Disease in Dialysis Patients and is Associate Editor of Atherosclerosis and Academic Editor of PLoS One. Advisory Board: Genzyme, Keryx Speaker: Amgen; Genzyme Rulan S Parekh, MD, MS, FRCP(C), FASN, is a Clinician Scientist and Associate Professor of Medicine and Paediatrics at the University of Toronto, The Hospital for Sick Children and University Health Net- work. The focus of Dr. Parekh s research is to study risk factors both clinically and genetically leading to progression of CKD and CVD. She has published over 80 peer reviewed manuscripts and book chapters, and has mentored over 25 postdoctoral fellows and students. She leads the NIH-NIDDK sponsored Predictors in Arrhythmic and Cardiovascular Disease in End Stage Renal Disease (PACE) , a new cohort study in dialysis patients to identify risk factors for sudden cardiac death. She is currently the chair of the American Kidney Fund Clinical Scientist Committee and on the Board of Trustees of the American Kidney Fund. She has recently been inducted into the American Society of Clinical Investigation and Society for Pediatric Research and has received awards for Advising, Teaching and Mentoring Award from the Johns Hopkins Bloomberg School of Public Health. She is presently an Associate Editor for BMC Nephrology and on the editorial board of the Clinical Journal of the American Society of Nephrology. Trustee: American Kidney Fund (no compensation) Grant/Research Support: Physician Services Inc* *monies paid to institution Tetsuo Shoji, MD, PhD, is affiliated with the Department of Geriatrics and Vascular Medicine, Osaka City Univer- sity Graduate School of Medicine, Osaka, Japan. 